Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • TBK1 and beyond

    Biogen and partners link mutant TBK1 to autophagy and neuroinflammation in ALS

    Biogen's collaboration with Columbia and HudsonAlpha has linked mutations in TBK1 with ALS in about 1% of patients, but the partners believe the finding could extend to many more.

    Published on 3/12/2015
  • Figure: Disaggregation factor

    TBK1 and beyond Targets & Mechanisms Disaggregation factor As reported in Science, exome sequencing on patients with amyotrophic lateral sclerosis (ALS) has highlighted TBK1 as a key player with a role in the …

    Published on 3/12/2015
  • Table: LRRK2 inhibitors for Parkinson's disease

    A LRRKing safety problem Targets & Mechanisms LRRK2 inhibitors for Parkinson's disease Data reported in Fuji, R., et al. suggest leucine-rich repeat kinase 2 (LRRK2) inhibition causes toxicity in nonhuman primates.…

    Published on 2/26/2015
  • A LRRKing safety problem

    Genentech's negative data on LRRK2 inhibitors brings stakeholders together

    Genentech has taken the unusual step of publishing negative safety data from its preclinical LRRK2 program, and The Michael J. Fox Foundation is pulling stakeholders together to determine the clinical implications.

    Published on 2/26/2015
  • Ace of hearts

    Beat BioTherapeutics takes aim at heart failure with dATP-boosting gene therapy

    Beat BioTherapeutics has a gene therapy for heart failure that provides energy via dATP instead of ATP, and is looking for series A funding to help test the concept in the clinic.

    Published on 2/19/2015
  • High five for Arsanis

    Arsanis finds neutralizing antibody against five Staphylococcus aureus toxins

    Arsanis used Adimab's technology to find an antibody that hits five bacterial toxins from one pathogen, and the bet is that the approach can fish out other hot-spot epitopes.

    Published on 2/12/2015
  • Figure: A hole in five toxins

    High five for Arsanis Targets & Mechanisms A hole in five toxins Finding antibodies that cross-react with multiple toxins from Staphylococcus aureus is a long shot given the low 25-27% homology between the organism…

    Published on 2/12/2015
  • Going TIGITal

    Genentech is combining antibodies against TIGIT and PD-L1 for cancer immunotherapy

    Genentech's discovery that TIGIT acts as a fine tuner for PD-1 via a new mechanism creates possibilities for combination therapies, but the company isn't revealing its plans.

    Published on 1/29/2015
  • Figure: TIGITal signaling

    Going TIGITal Targets & Mechanisms TIGITal signaling The CD226 and TIGIT co-signaling receptor pathway on T cells. I. On activated T cells, CD226 forms homodimers to interact with its ligand, PVR, on antigen-…

    Published on 1/29/2015
  • Personalized tumor vaccines

    Personalized tumor vaccines derived from tumor-specific mutant epitopes

    Mutant antigens in tumor cells targeted by anti-PD-1 therapies can be used to generate tumor-specific vaccines, and might mark the start of personalized combos in immunotherapy.

    Published on 1/29/2015
  • Unearthing antibiotics

    New antimicrobial peptides from soil bacteria

    Two new techniques for exploiting soil bacteria to find antibiotics have uncovered compound classes and targets that could impact the field even more than the pair of antimicrobials discovered.

    Published on 1/22/2015
  • Pseudo-allergy exposed

    One receptor could help screen out allergy-inducing compounds during discovery

    A single receptor found to mediate allergic drug reactions could lead to an antidote and allow compounds to be screened out early during drug discovery.

    Published on 1/22/2015
  • Figure: The THIQ IQ

    Pseudo-allergy exposed Targets & Mechanisms The THIQ IQ Structures of the classic basic secretagogue 48/80, its cyclized monomer and representative members of neuromuscular blocking or anti-microbial drugs that …

    Published on 1/22/2015
  • Box: Dirt Silk Road

    Unearthing antibiotics Targets & Mechanisms Dirt silk road Historically, soil-based bacteria were routinely mined for antibiotics, but the practice has lost ground to synthetic approaches involving structure-based …

    Published on 1/22/2015
  • Resurrecting a magic bullet

    Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform.

    Published on 12/18/2014
  • Lysin in wait

    Micreos and ContraFect are separately developing phage lysins, which are not prone to bacterial resistance, as complements to antibiotics.

    Published on 12/11/2014
  • PIEZO de resistance

    A Duke team has found a new role for PIEZO calcium channels in cartilage damage, suggesting channel inhibitors could be developed for joint injury or osteoarthritis.

    Published on 12/11/2014
  • Terazosin reborn

    Chinese researchers have found that the generic alpha-blocker terazosin prevents apoptosis and want to pursue it for stroke, but they will need to navigate a landscape of difficult preclinical models.

    Published on 12/11/2014
  • Greasing insulin

    The once discarded target GPR120 has led to the discovery of an entirely new class of fatty acids that could restore insulin sensitivity in patients with diabetes.

    Published on 11/6/2014
  • Branching out in pancreatic cancer

    Changes in circulating levels of branched-chain amino acids detectable 2-5 years before the onset of pancreatic cancer could lead to diagnostic markers for the indication.

    Published on 10/23/2014
  • Alnylam interrupts preeclampsia

    Alnylam has generated an siRNA conjugate that blocks angiotensin-induced hypertension without causing fetal toxicity in a rat model of preeclampsia.

    Published on 10/16/2014
  • BetaLogics' in vitro beta cells

    BetaLogics and University of British Columbia researchers have developed an in vitro protocol to generate mature insulin-producing beta-like cells from human pluripotent stem cells - a major milestone in the development…

    Published on 10/9/2014
  • MIDAS touch vaccine

    A vaccine against the fibrinogen-binding MIDAS domain in the ebpA protein of Enterococcus faecalis could provide a solution to the widespread problem of catheter-associated urinary tract infections.

    Published on 10/9/2014
  • Ral-lying around Ras

    A University of Colorado-led team has demonstrated anticancer efficacy for new small molecule inhibitors of Ral proteins - a family of Ras-like GTPases often overlooked in favor of their Ras cousins.

    Published on 10/9/2014
  • ALK7's obese functions

    Researchers have shown that inhibiting ALK7 can increase energy expenditure in fat cells and suggest the protein could be a target for obesity. Acceleron Pharma has licensed the findings and is pursuing a discovery …

    Published on 9/25/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993